HOPA's Practice Outcomes and Professional Benchmarking Committee (POPBC) conducted a multi-organization, voluntary survey of HOPA members between March of 2021 and January of 2022. The purpose was to better understand the landscape of oncology pharmacy at healthcare organizations throughout the United States.

The research examined: institutional description, job function, staffing, and training/certification. Data were evaluated using descriptive statistics. The analysis found that as the number of patients with cancer rises, the oncology workforce must grow. The current oncology pharmacy practice landscape can serve as a foundation for future research, metrics, and benchmarks.

This research was published in the Journal of Oncology Pharmacy Practice.

Authors: Shawn P Griffin, Jessie R Signorelli, Aubrey Lasko, Benjamin J Andrick, David Doan, Shannon Hough, Grazyna Riebandt, and Stephen Harnicar

Read the paper
Advocacy

Related Articles

Read all latest news Right Pointing Arrow
U.S. Capitol Building
Advocacy

What HOPA Members Should Know About the End of the 2025 U.S. Government Shutdown

November 14, 2025

On Wednesday, November 12, Congress passed a continuing resolution to re-open the government after a record 43-day shutdown. Here's what HOPA members should know about the bill and what's happening next.

Map of the sub-Saharan African region
Advocacy

HOPA Endorses ISOPP & UICC Statement on Ensuring International Cancer Drug Quality and Equity

November 04, 2025

ISOPP and UICC recently released a statement calling for quality and equity of cancer treatments in sub-Saharan Africa. HOPA has joined with oncology and pharmacy organizations worldwide to endorse their statement.

Images of DNA strands for DPYD genetic testing
Advocacy

HOPA Supports FDA Box Label Changes for DPYD Testing

October 24, 2025

We support the FDA's updated guidance concerning DPD deficiency and fluoropyrimidine drugs, and urge healthcare providers to integrate DPYD genetic testing into clinical practice.